About SmartPractice Dermatology|Allergy

Our Dermatology|Allergy division exists because patients deserve a diagnosis™. It started with our CEO/Medical Director’s passion to help a young dental assistant find the cause of her hand dermatitis. Developed over the course of the past 10 years, our multi-brand, multi-product Dermatology | Allergy division now focuses on providing innovative products to help diagnose and treat patients with allergic contact dermatitis. This division also helps educate new patch testers and conducts clinical research studies to improve the understanding of allergens to help improve the diagnosis of allergic contact dermatitis.

SmartPractice is the manufacturer and North American distributor of T.R.U.E. TEST, Finn Chambers®, allergEAZE®, TruVol™, TruCase™, Reveal & Conceal™, patchProtect™, patchMap™ and patchTransport™. Through our investments in technology, clinical science, and world-class service, SmartPractice is committed to "all things contact dermatitis"™ for physicians and patients.

Company Timeline

1969 - Semantodontics founded as a distributor of supplies to dental practices
1985 - Semantodontics expanded offering to medical practices
1988 - Semantodontics renamed SmartPractice
2004 - SmartPractice acquired Allerderm Laboratories and launches Dermatology | Allergy Division
2006 - SmartPractice acquired Mekos Labs manufacturer and global distributor of T.R.U.E. TEST
2006 - SmartPractice Canada founded to sell allergens under the allergEAZE brand name
2008 - SmartPractice acquired Epitest/Finn Chambers
2010 - SmartPractice Germany founded to sell products to German Dermatologists
2012 - SmartPractice acquired Hayes Chamber (rebranded as allergEAZE chambers)
2013 - SmartPractice acquired EpiCutantest Hermal/TROLAB business (SmartPractice Europe founded)
2014 - SmartPractice launched TruVol Precision Allergen Dispenser
2015 - SmartPractice Europe merger with brial allergen (Greven, Germany)
2016 - SmartPractice launched TruCase Allergen Attache
2017 – SmartPractice received FDA approval for the use of T.R.U.E. TEST on patients as young as 6 years old